Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Muff, R., Buhlmann, N., Fischer, J
Get your treatment plan Once a Hers service professional has assessed your profile, they will advise you on a treatment plan
Key Highlights (72 weeks study): Resolution of steatohepatitis: 62.9% (semaglutide) vs 31.5% (placebo) Fibrosis improvement (1 stage): 36.8% vs 22.4% Average weight reduction: ~10% Better metabolic and liver markers Safety: Mostly mildmoderate GI side effects While semaglutide is not yet an approved antifibrotic, this data represents a major advancement in addressing both metabolic and hepatic components of the disease
Preserved Acetylcysteine A powerful antioxidant precursor that boosts glutathione production
